Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

Thus, Thermo Fisher researchers are confident that the anti-EGFR antibody is target-specific. In the cell nucleus, DNA is tightly packaged — wrapped around histone proteins to form chromatin.

肺癌的主要亚型非小细胞肺腺癌有比较大的概率可以靶向治疗，对于亚裔的非小细胞肺腺癌患者来说，EGFR基因突变概率非常高，可以达到50%的突变 ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...